• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CRO top executives in a game of ‘musical chairs’

CRO top executives in a game of ‘musical chairs’

November 7, 2011
CenterWatch Staff

Five months after INC Research’s acquisition of Kendle International closed, executives from the now-combined CRO are landing jobs with competitors.  

On Nov. 2, CRO Theorem Clinical Research announced it had hired John Potthoff, formerly INC’s chief operating officer, to be its president and CEO. One day before, Icon announced it had hired Stephen Cutler, president and CEO of Kendle only since May 1, to be group president of clinical research services. Culter had left INC-Kendle when the acquisition closed in July. 

Analysts say this is just the ‘musical chairs’ natural order of things after such a merger in the CRO space. As John Kreger, financial analyst with William Blair, put it, “No company needs two CEOs.”  

An industry source, who asked to not be named, said, “The CEO of the company doing the buying usually isn’t the CEO who loses his job.” 

Another source who spoke off the record was surprised INC didn’t tap these men for other high-level positions in the company. “Big companies like that have an awful lot of divisions that need to be headed up, and INC is not quite fully staffed,” he said.  

Kreger said that despite moving from president and CEO of Kendle to group president of clinical research services for Icon, Cutler did not really take a step down. “From a responsibility standpoint, it’s a step down not being a CEO anymore, but he’s going to a much bigger and historically more successful company, so it evens out.”  

Potthoff succeeds James Pusey, who now becomes Theorem’s executive chairman to the board of directors. 

Theorem is the new entity born when publicly traded pharmaceutical distributor Omnicare spun off its CRO holdings, selling them to equity investment firm Nautic Partners in April 2011. Pusey became president and CEO of the Omnicare CRO in 2009, tasked with fixing the ailing division and transitioning it through its spin off and sale. Pusey had previously joined MDS Pharma Services in 2006 with the same mission for its late-phase CRO operations. That job was completed in 2009, with a sale to INC.  

Icon said Alan Morgan, who Cutler is replacing, “has resigned from his position... to pursue other opportunities.” Interestingly, Morgan worked with MDS’ late-phase operations before joining Icon.  

Potthoff had been with INC since 2001 when Tanistry, a CNS-focused CRO he founded, was bought by the company. During his time at INC, Potthoff lead CNS therapeutics, global business development and clinical development in North America. Prior to founding Tanistry and serving as its president and CEO, Potthoff spent seven years at PPD. 

Before becoming president and CEO of Kendle, Cutler had been chief operating officer of the company. Prior to that, he spent 14 years with Quintiles, where he held a variety of roles, including senior vice president of global project management and senior vice president of clinical, medical and regulatory. Before Quintiles, Cutler worked for Sandoz (now Novartis) in Australia and Europe.  

Both Theorem and Icon are beefing up their ranks as well as shifting people around.  

In late October, Theorem announced it had hired Adam Serody from PharmaNet to lead Thereom’s global sales, proposals and marketing organizations. He had been executive director of business development and global leader for phase IV at PharmaNet.  

In early October, Icon announced Colin Stanley was taking over as president of the company’s global resourcing division following the retirement of Bill Taaffe earlier this year. Stanley previously had been chief operating officer of DOCS. 

Suz Redfearn

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing